vertex journavx - Search News

New non-opioid painkiller Journavx approved by FDA

YAHOO!Finance · 1h

FDA approves Vertex’s acute pain treatment Journavx

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with acute pain. The FDA has approved the non-opioid, highly selective NaV1.8 pain signal inhibitor for administration twice daily.

Hosted on MSN · 9h

What Is Journavx? First Pain Medication Approved by FDA in Over Two Decades

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

BioSpace · 11h

FDA Approves Vertex’s Journavx as First New Pain Drug in Decades

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum in the fledgling non-opioid pain space.

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

11h

Vertex Pharmaceuticals’ non-opioid Journavx approved for pain by FDA

Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results